Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 15;585:145–154. doi: 10.1016/j.virol.2023.06.005

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Construction and identification of Trim-RBD protein.

(a) Design of Trim-RBD structures, MSP: mastoparan; PA: protein anchor; linker5: (GGGGS)5 linker; T4F: T4 fibritin foldon domain. (b) Indirect immunofluorescence identification of recombinant baculovirus, infected with Sf9 cells at 3% volume ratio, incubated with rabbit anti-SARS-CoV-2 RBD protein antibody. (c) Western blot identification of recombinant baculovirus with non-reduction treatment; lane 1 is recombinant baculovirus supernatant, and lane 2 is recombinant baculovirus precipitate, and lane 3 is baculovirus (BV) culture suspensions. (d) Western blot identification of recombinant baculovirus with reduction treatment; lane 1 is recombinant baculovirus supernatant, lane 2 is recombinant baculovirus precipitate, and lane 3 is BV culture cell suspension.